Trading statement for the year ended 30 September 2026
Trading statementMaterial
In brief
For the year ended 30 September 2026, normalised EPS from continuing operations is expected to rise 6% to 11% to between +106.3 cents and +111.3 cents. Total HEPS is expected between +96.0 cents and +100.5 cents.
The announcement
Trading statement for the year ended 30 September 2026 LIFE HEALTHCARE GROUP HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number: 2003/002733/06) ISIN: ZAE000145892 JSE and A2X share code: LHC ("Life Healthcare" or "the Group" or "the Company") LIFE HEALTHCARE FUNDING LIMITED (Incorporated in the Republic of South Africa with limited liability) (Registration number 2016/273566/06) LEI: 3789SJPQJZF8ZYXTZ394 Bond company code: LHFI (“Life Healthcare Funding”) TRADING STATEMENT FOR THE YEAR ENDED 30 SEPTEMBER 2026 As previously communicated, the earnings for the year ended 30 September 2026 (current year) have been significantly impacted by the disposal of Life Molecular Imaging (LMI) in FY2025 (prior year), distorting the comparability between the two financial periods. The disposal of LMI in the prior year resulted in a R2.4 billion net gain. Due to the required accounting treatment of the disposal, it impacted earnings per share (EPS) and headline earnings per share (HEPS) to various degrees. The fair value adjustment of R2.9 billion included in the net gain impacted EPS and HEPS from continuing and discontinued operations and, due to the pre-existing nature of the Piramal liability (which remains with the Group), it also impacted both EPS and HEPS from continuing operations. The fair value adjustment was, however, excluded from normalised earnings per share (NEPS). The table below summarises the expected earnings for the current year. NEPS, which excludes non-trading related items, better reflects the performance of our southern African underlying business. Earnings per share FY2026 FY2025 Pro forma Pro forma % change Pro forma (cents) (expected) (reported) adjustments FY2025 FY2026 % change FY2025 (reported) (expected) vs FY2026 (reported) (note 1) FY2025 (expected) vs (reported) FY2025 (pro forma) From continuing operations NEPS +106.3 to +111.3 100.3 - 100.3 6% to 11% 6% to 11% EPS +94.1 to +98.8 -106.9 201.0 94.1 >100% 0% to 5% HEPS +100.7 to 106.0 -93.9 201.0 107.1 >100% -1% to - 6% From continuing and discontinued operations EPS +84.2 to +97.3 263.0 - 263.0 -63% to -68% -63% to -68% HEPS +96.0 to +100.5 -112.1 201.0 88.9 >100% +8% to +13% Notes 1. Pro forma information To provide a more realistic assessment of the Group’s performance for the prior year, pro forma financial information has been included in this announcement. The FY2025 pro forma numbers are derived by adding back the fair value adjustment relating to the Piramal liability to the FY2025 audited results. The directors are responsible for the pro forma financial information, which has been prepared in compliance with paragraphs 11.8 to 11.18 of the Listings Requirements of the JSE Limited and the SAICA Guide on Pro forma Financial Information, revised and issued in September 2014 (applicable criteria). The pro forma information does not constitute financial information fairly presented in accordance with IFRS Accounting Standards. The pro forma information has been prepared for illustrative purposes only and, due to its nature, may not fairly present the Group’s financial position, changes in equity, results of operations or cash flows. The underlying information used in the preparation of the pro forma financial information has been prepared using the accounting policies of the Group in place for FY2026. The Group’s FY2026 results are still in the process of being finalised. Life Healthcare expects to release its results for the year ended 30 September 2026 on or about 26 November 2026. The estimated financial information on which this trading statement is based has not been reviewed, or reported on, by Life Healthcare’s external auditors. For further information, please email: Investor.Relations@lifehealthcare.co.za Dunkeld 12 November 2026 Equity Sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited) Debt Sponsor: Questco Corporate Advisory Date: 12/11/2026 02:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.